Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma

Loading news article.

Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma | WAPE

Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma

Article summary

Related companies

Comments —